Exploratory Study of Personalized mRNA Vaccine in Patients With Refractory Rhabdomyosarcoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

EARLY_PHASE1

Total Enrollment

5 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-05-01

Study Completion Date

2028-05-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

An Exploratory Study on the Use of mRNA Tumor Vaccines in the Treatment of Refractory Rhabdomyosarcoma

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Personalized Neoantigen MRNA Vaccine Combined with Adebrelimab in Non-Small Cell Lung Cancer Patients

NCT06685653

NSCLC

NOT_YET_RECRUITING EARLY_PHASE1

Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Combination With Standard First-line Treatment in Subjects With Advanced Digestive System Neoplasms

NCT06026800

Digestive System Neoplasms

RECRUITING PHASE1

Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen Alone in Subjects With Advanced Digestive System Neoplasms

NCT06019702

Digestive System Neoplasms

RECRUITING PHASE1

A Study of RC148 As a Single Agent and Combination Therapy in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors

NCT06016062

Solid Tumor

RECRUITING PHASE1/PHASE2

Anti-cancer Neoantigen mRNA Vaccine to Treat Solid Tumors

NCT06195384

Solid Tumor, Adult

RECRUITING PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rhabdomyosarcoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vaccine arm

Group Type EXPERIMENTAL

mRNA Tumor Vaccine Therapy

Intervention Type BIOLOGICAL

personalized mRNA vaccines

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

mRNA Tumor Vaccine Therapy

personalized mRNA vaccines

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Diagnosed with rhabdomyosarcoma confirmed by pathological or molecular testing;
2. Age ≥ 6 years;
3. No known effective treatment available or no treatment proven to prolong survival with an acceptable quality of life;
4. Expected survival time greater than 6 months;
5. ECOG performance status score of 0-1; -

Exclusion Criteria

* 1.History of or concurrent with other untreated malignant tumors, except for previously cured basal cell carcinoma of the skin, carcinoma in situ of the cervix, and superficial bladder cancer; 2.History of or current active autoimmune diseases. 3.Has uncontrolled cardiovascular diseases.

Minimum Eligible Age

6 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No